Evidence map›Paper›PMID 34896662›Full record

Observational studyInfectious diseases now2022

Pulmonary bacterial infections in adult patients hospitalized for COVID-19 in standard wards.

M Husain, S Valayer, N Poey, E Rondinaud, C d'Humières, B Visseaux, S Lariven, F X Lescure, L Deconinck

Open access · greenAbstract readObservational Study
In one paragraph

Observational study in Infectious diseases now, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Infectious disease reports · 2024
    Article
  2. Co-Infection of SARS-CoV-2 andDiagnostics (Basel, Switzerland) · 2024
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

M HusainInfectious and tropical diseases department, Bichat Hospital, Paris, France; Faculty of medicine, University of Paris, Paris, France.
S ValayerInfectious and tropical diseases department, Bichat Hospital, Paris, France; Faculty of medicine, Sorbonne University, Paris, France.
N PoeyInfectious and tropical diseases department, Bichat Hospital, Paris, France. Electronic address: nora.poey@aphp.fr.
E RondinaudBacteriology department, Bichat Hospital, Paris, France; Inserm, IAME, UMR 1137, University of Paris, Paris, France.
C d'HumièresBacteriology department, Bichat Hospital, Paris, France; Inserm, IAME, UMR 1137, University of Paris, Paris, France.
B VisseauxVirology department, Bichat Hospital, Paris, France.
S LarivenInfectious and tropical diseases department, Bichat Hospital, Paris, France.
F X LescureInfectious and tropical diseases department, Bichat Hospital, Paris, France.
L DeconinckInfectious and tropical diseases department, Bichat Hospital, Paris, France.
Hôpital Bichat-Claude-Bernard · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesDuring the COVID-19 pandemic, antibiotic use was very common. However, bacterial co-/secondary infections with coronaviruses remain largely unknown in standard wards. We aimed to investigate the characteristics of pulmonary bacterial infections associated with COVID-19 in hospitalized patients.

methodsA retrospective monocentric observational study was conducted in Bichat hospital, France, between February 26 and April 22, 2020. All patients hospitalized in standard wards with COVID-19 (positive nasopharyngeal PCR and/or typical aspect on CT-scan) and diagnosed with pulmonary bacterial infection (positive bacteriological samples) were included. Bacteriological and clinical data were collected from the microbiology laboratories and patient's medical records.

resultsTwenty-three bacteriological samples from 22 patients were positive out of 2075 screened samples (1.1%) from 784 patients (2.8%). Bacterial infection occurred within a median of 10 days after COVID-19 onset. Diagnosis of pulmonary bacterial infection was suspected on increase of oxygen requirements (20/22), productive cough or modification of sputum aspect (17/22), or fever (10/22). Positive samples included 13 sputum cultures, one FilmArray® assay on sputum samples, one bronchoalveolar lavage, six blood cultures, and two pneumococcal urinary antigen tests. The most frequent bacteria were Pseudomonas aeruginosa (6/23), Staphylococcus aureus (5/23), Streptococcus pneumoniae (4/23), Enterococcus faecalis (3/23), and Klebsiella aerogenes (3/23). No Legionella urinary antigen test was positive. Four out of 496 nasopharyngeal PCR tests (0.8%) were positive for intracellular bacteria (two Bordetella pertussis and two Mycoplasma pneumonia).

conclusionsPulmonary bacterial secondary infections and co-infections with SARS-CoV-2 are uncommon. Antibiotic use should remain limited in the management of COVID-19.

Indexed as

Bacterial InfectionsCoinfectionCOVID-19AdultAnti-Bacterial AgentsBacteriaHospitalsHumansPandemicsRetrospective StudiesSARS-CoV-2Anti-Bacterial AgentsBacterial infectionCo-infectionPneumoniaSARS-CoV-2Secondary infection

Identifiers

PMID34896662
PMCPMC8656209
OpenAlexW4200432402

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.